{"id":"https://openalex.org/W1964440779","doi":"https://doi.org/10.1016/j.eurpsy.2014.12.002","title":"The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies","display_name":"The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies","alternate_titles":[],"publication_year":2015,"publication_date":"2015-06-01","ids":{"openalex":"https://openalex.org/W1964440779","doi":"https://doi.org/10.1016/j.eurpsy.2014.12.002","mag":"1964440779","pmid":"https://pubmed.ncbi.nlm.nih.gov/25649490"},"language":"en","primary_location":{"id":"doi:10.1016/j.eurpsy.2014.12.002","doi":"https://doi.org/10.1016/j.eurpsy.2014.12.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.eurpsy.2014.12.002","pdf_url":null,"source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1964440779"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017195801","display_name":"Philip J. Asherson","orcid":"https://orcid.org/0000-0003-2667-2254","observed_orcids":["https://orcid.org/0000-0003-2667-2254"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"P. Asherson","raw_affiliation_strings":["Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, King's College London, De Crespigny Park SE5 8AF, United Kingdom. Electronic address: philip.asherson@kcl.ac.uk","Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, King's College London, De Crespigny Park SE5 8AF, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, King's College London, De Crespigny Park SE5 8AF, United Kingdom. Electronic address: philip.asherson@kcl.ac.uk","institution_ids":["https://openalex.org/I183935753"]},{"raw_affiliation_string":"Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, King's College London, De Crespigny Park SE5 8AF, United Kingdom","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016674464","display_name":"Steven Stes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Stes","raw_affiliation_strings":["ADHD Program, University Psychiatric Center, KU Leuven, Leuvensesteenweg 517, Campus Kortenberg, Belgium; Code Thomas More, Jozef De Bomstraat 11, 2018 Antwerpen, Belgium","ADHD Program, University Psychiatric Center, KU Leuven, Leuvensesteenweg 517, Campus Kortenberg, Belgium","Code Thomas More, Jozef De Bomstraat 11, 2018 Antwerpen, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ADHD Program, University Psychiatric Center, KU Leuven, Leuvensesteenweg 517, Campus Kortenberg, Belgium; Code Thomas More, Jozef De Bomstraat 11, 2018 Antwerpen, Belgium","institution_ids":["https://openalex.org/I99464096"]},{"raw_affiliation_string":"ADHD Program, University Psychiatric Center, KU Leuven, Leuvensesteenweg 517, Campus Kortenberg, Belgium","institution_ids":["https://openalex.org/I99464096"]},{"raw_affiliation_string":"Code Thomas More, Jozef De Bomstraat 11, 2018 Antwerpen, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009412797","display_name":"Maria Nilsson Markhed","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Nilsson Markhed","raw_affiliation_strings":["Department of Psychiatry, Uppsala University, 751 85, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Uppsala University, 751 85, Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023377934","display_name":"Lovisa Berggren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110958","display_name":"Eli Lilly (Germany)","ror":"https://ror.org/01pmvz131","country_code":"DE","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210110958"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L. Berggren","raw_affiliation_strings":["Global Statistical Sciences, Eli Lilly & Co., Werner Reimers Str. 2-4, 61350 Bad Homburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Statistical Sciences, Eli Lilly & Co., Werner Reimers Str. 2-4, 61350 Bad Homburg, Germany","institution_ids":["https://openalex.org/I4210110958"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038445300","display_name":"P\u00e4r Svanborg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Svanborg","raw_affiliation_strings":["Neuroscience, Eli Lilly & Co., Sweden AB, Gustav III Boulevard 42, PO box 721, SE-169 27 Solna, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neuroscience, Eli Lilly & Co., Sweden AB, Gustav III Boulevard 42, PO box 721, SE-169 27 Solna, Sweden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074727500","display_name":"Alexandra Kutzelnigg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Kutzelnigg","raw_affiliation_strings":["Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","institution_ids":["https://openalex.org/I76134821"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044285961","display_name":"Walter G. Deberdt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"W. Deberdt","raw_affiliation_strings":["Medical Department, Eli Lilly & Co., Markiesstraat 1, 1000 Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Department, Eli Lilly & Co., Markiesstraat 1, 1000 Brussels, Belgium","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5017195801"],"corresponding_institution_ids":["https://openalex.org/I183935753"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":null,"fwci":1.9039,"has_fulltext":false,"cited_by_count":26,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.82723577,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"30","issue":"4","first_page":"511","last_page":"520"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atomoxetine","display_name":"atomoxetine","score":1.0},{"id":"https://openalex.org/keywords/adult-adhd","display_name":"adult ADHD","score":0.9160000085830688},{"id":"https://openalex.org/keywords/emotional-control","display_name":"emotional control","score":0.996999979019165},{"id":"https://openalex.org/keywords/brief-a","display_name":"BRIEF-A","score":0.7480000257492065},{"id":"https://openalex.org/keywords/executive-function","display_name":"executive function","score":0.7889999747276306},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.8339999914169312},{"id":"https://openalex.org/keywords/individual-patient-data-pooling","display_name":"individual patient data pooling","score":0.6489999890327454},{"id":"https://openalex.org/keywords/treatment-effects","display_name":"treatment effects","score":0.39500001072883606}],"concepts":[{"id":"https://openalex.org/C2778781522","wikidata":"https://www.wikidata.org/wiki/Q417240","display_name":"Atomoxetine","level":4,"score":0.9359329342842102},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.702987015247345},{"id":"https://openalex.org/C44725695","wikidata":"https://www.wikidata.org/wiki/Q288156","display_name":"Normative","level":2,"score":0.6063045263290405},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5694341659545898},{"id":"https://openalex.org/C2909253567","wikidata":"https://www.wikidata.org/wiki/Q417240","display_name":"Atomoxetine hydrochloride","level":5,"score":0.5663427114486694},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5607302784919739},{"id":"https://openalex.org/C70410870","wikidata":"https://www.wikidata.org/wiki/Q199906","display_name":"Clinical psychology","level":1,"score":0.4859682321548462},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.45524686574935913},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.44622865319252014},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3635890781879425},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36164188385009766},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.3613293468952179},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18213951587677002},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.09827771782875061},{"id":"https://openalex.org/C542102704","wikidata":"https://www.wikidata.org/wiki/Q183257","display_name":"Psychotherapist","level":1,"score":0.0727720856666565},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000069445","descriptor_name":"Atomoxetine Hydrochloride","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069445","descriptor_name":"Atomoxetine Hydrochloride","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004644","descriptor_name":"Emotions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D056344","descriptor_name":"Executive Function","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.eurpsy.2014.12.002","doi":"https://doi.org/10.1016/j.eurpsy.2014.12.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.eurpsy.2014.12.002","pdf_url":null,"source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},{"id":"pmid:25649490","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25649490","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European psychiatry : the journal of the Association of European Psychiatrists","raw_type":"Journal Article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/cac232d4-062c-4c7f-a496-5321b98d3d77","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/cac232d4-062c-4c7f-a496-5321b98d3d77","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Asherson, P, Stes, S, Nilsson Markhed, M, Berggren, L, Svanborg, P, Kutzelnigg, A & Deberdt, W 2015, 'The effects of atomoxetine on emotional control in adults with ADHD : An integrated analysis of multicenter studies', European Psychiatry, vol. 30, no. 4, pp. 511-520. https://doi.org/10.1016/j.eurpsy.2014.12.002","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G410938743","display_name":null,"funder_award_id":"RC-PG-0308-10245","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"},{"id":"https://openalex.org/F4320322202","display_name":"IC Design Education Center","ror":"https://ror.org/005v57z85"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W94022314","https://openalex.org/W1522095004","https://openalex.org/W1773116645","https://openalex.org/W1966900123","https://openalex.org/W1967986347","https://openalex.org/W1971318683","https://openalex.org/W1978693046","https://openalex.org/W1985528539","https://openalex.org/W1989415748","https://openalex.org/W2008176510","https://openalex.org/W2009260504","https://openalex.org/W2014193692","https://openalex.org/W2016511885","https://openalex.org/W2020006801","https://openalex.org/W2024945874","https://openalex.org/W2025163293","https://openalex.org/W2027005399","https://openalex.org/W2031129459","https://openalex.org/W2034397820","https://openalex.org/W2037861842","https://openalex.org/W2047791964","https://openalex.org/W2053886019","https://openalex.org/W2060511695","https://openalex.org/W2062542891","https://openalex.org/W2080388744","https://openalex.org/W2080595769","https://openalex.org/W2089663898","https://openalex.org/W2093528493","https://openalex.org/W2111135575","https://openalex.org/W2112281135","https://openalex.org/W2117104588","https://openalex.org/W2127237900","https://openalex.org/W2129129238","https://openalex.org/W2134134095","https://openalex.org/W2143556273","https://openalex.org/W2144288243","https://openalex.org/W2155679196","https://openalex.org/W2155877143","https://openalex.org/W2159011576","https://openalex.org/W2159881136","https://openalex.org/W2169121996","https://openalex.org/W2171147935","https://openalex.org/W2171204232","https://openalex.org/W2331041387","https://openalex.org/W3090293687","https://openalex.org/W3127611755","https://openalex.org/W3165519085","https://openalex.org/W4399074363","https://openalex.org/W6658796848"],"related_works":["https://openalex.org/W2020006801","https://openalex.org/W2617656397","https://openalex.org/W2129129238","https://openalex.org/W2031129459","https://openalex.org/W4285392517","https://openalex.org/W2320971047","https://openalex.org/W2517735657","https://openalex.org/W1966900123","https://openalex.org/W2053886019","https://openalex.org/W2053295943"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"investigate":[2],"the":[3,93,124,130,171,227],"effects":[4],"of":[5,39,56,69,97,105,120],"atomoxetine":[6,133,231],"on":[7],"emotional":[8,147,165,180,203,221,238],"control":[9,111,159,166,181,204,222],"in":[10,92,123,129,154,164,170,202,237,243],"adults":[11,212],"with":[12,58,72,118,156,168,184,213,235],"ADHD.":[13],"METHODS:":[14],"We":[15],"performed":[16],"an":[17],"integrated":[18,31],"analysis":[19,32],"using":[20],"individual":[21,40],"patient":[22],"data":[23,61,75],"pooled":[24],"from":[25,76],"three":[26],"Eli":[27],"Lilly-sponsored":[28],"studies.":[29],"An":[30],"can":[33],"be":[34,206],"viewed":[35],"as":[36,240,242],"a":[37,53,67,136],"meta-analysis":[38],"patient-level":[41],"data,":[42],"rather":[43],"than":[44,223],"study-level":[45],"summary":[46],"data.":[47],"RESULTS:":[48],"Two":[49],"populations":[50],"were":[51,215],"identified:":[52],"large":[54],"sample":[55],"patients":[57,71,99,155],"pre-treatment":[59],"baseline":[60,77],"(the":[62,86],"\"overall":[63],"population\";":[64,88],"n=2846);":[65],"and":[66,115,175,188,192,247],"subset":[68],"these":[70],"placebo-controlled":[73,131],"efficacy":[74],"to":[78,135,218],"10":[79],"or":[80],"12":[81],"weeks":[82],"after":[83],"initiating":[84],"treatment":[85,144,232],"\"placebo-controlled":[87],"n=829).":[89],"At":[90,127,210],"baseline,":[91,211],"overall":[94],"population,":[95,132],"\u223c50%":[96],"ADHD":[98,173,198,214,229,245],"had":[100],"BRIEF-AS":[101,157],"(Behavior":[102],"Rating":[103],"Inventory":[104],"Executive":[106],"Function-Adult":[107],"Version":[108],"Self-Report)":[109],"Emotional":[110,158],"subscores":[112],"between":[113],"21":[114],"30,":[116],"compared":[117],"\u223c10%":[119],"normative":[121,224],"subjects":[122],"BRIEF-A":[125],"manual.":[126],"endpoint,":[128],"led":[134],"small":[137],"(effect":[138],"size":[139,151],"0.19)":[140],"but":[141],"significant":[142],"(P=0.013)":[143],"effect":[145,150],"for":[146],"control.":[148],"The":[149],"was":[152,233],"0.32":[153],"scores>20":[160],"at":[161],"baseline.":[162],"Improvements":[163],"correlated":[167],"improvements":[169,201,236],"core":[172,197,244],"symptoms":[174,199,246],"quality-of-life.":[176,248],"DISCUSSION:":[177],"As":[178],"deficient":[179],"is":[182],"associated":[183,234],"impaired":[185,220],"social,":[186],"educational":[187],"occupational":[189],"functioning":[190],"over":[191],"above":[193],"that":[194],"explained":[195],"by":[196],"alone,":[200],"may":[205],"clinically":[207],"relevant.":[208],"CONCLUSION:":[209],"more":[216],"likely":[217],"have":[219],"subjects.":[225],"In":[226],"adult":[228],"patients,":[230],"control,":[239],"well":[241]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1964440779","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
